Short analytical review: Tumor necrosis factor-α blockade: A novel therapy for rheumatic disease

Clinical Immunology

Volumn 103, Issue 3 I, 2002, Pages 231-242

  Shanahan, Joseph C ^a   St Clair, E William ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; BLOCKING ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

APLASTIC ANEMIA; ARTICULAR CARTILAGE; BLOOD TRANSFUSION REACTION; DEMYELINATING DISEASE; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITY OF LIFE; RASH; RECEPTOR BLOCKING; REVIEW; RHEUMATIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036594572     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2002.5191     Document Type: Review

References (106)

1. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
2. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects
3. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial
4. Comparison of combination therapy with single drug therapy in early rheumatoid arthritis: A randomized trial
5. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: A double-blind placebo-controlled study
6. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
7. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
8. Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: Prolonged production of IL-1α
9. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
10. Expression of granulocyte-macrophage colony stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α
11. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin- 1 receptor antagonist
12. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
13. Involvement of endogenous tumour necrosis factor-α and transforming growth factor-β during induction of collagen type II arthritis in mice
14. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor-α antibody or a recombinant soluble TNF receptor
15. Influence of a recombinant human soluble tumor necrosis factor receptor: Fc fusion protein on type II collagen-induced arthritis in mice
16. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD 4
17. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis
18. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α
19. Decrease in the cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody in patients with rheumatoid arthritis
20. Regulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-α therapy in rheumatoid arthritis
21. Reduction of matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients
22. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor-α and interleukin-1 in rheumatoid arthritis
23. Repeated therapy with monoclonal antibody to tumor necrosis factor-α (cA2) in patients with rheumatoid arthritis
24. Infliximab (chimeric anti-tumor necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
25. Preliminary definition of improvement in rheumatoid arthritis
26. Infliximab and methotrexate in the treatment of rheumatoid arthritis
27. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability
28. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
29. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
30. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
31. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
32. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint
33. The erosive front: A topographic study of the junction between the pannu 7s and the subchondral plate in the macerated rheumatoid metacarpal head
34. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
35. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
36. Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to bone surface
37. 1 integrins
38. Identification of matrix metalloproteinase 9 in rabbit osteoclasts
39. Molecular cloning of a possible cysteine protease predominantly expressed in osteoclasts
40. Molecular cloning of human cDNA for cathepsin K: Novel proteinase predominantly expressed in bone
41. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
42. Bone acid phosphatase: Tartrate-resistant acid phosphatase as marker of osteoclast function
43. Demonstration of tartrate-resistant acid phosphatase in undecalcified, glycolmethacrylate-embedded mouse bone: A possible marker for (pre)osteoclast identification
44. Stimulation of bone resorption and inhibition of bone formation by human tumour necrosis factors
45. Tumor necrosis factor-α stimulates resorption and inhibits synthesis of proteoglycan in cartilage
46. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E 2 production by human synovial cells and dermal fibroblasts
47. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
48. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogensis
49. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
50. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
51. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells
52. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
53. Interleukin-1-β and tumor necrosis factor-α, but not interleukin- 6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
54. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production
55. 5 integrin expression by osteoclast precursors in vitro and in vivo
56. Carbonic anhydrase II mRNA expression in individual osteoclasts under "resorbing" and "nonresorbing" conditions
57. v-associated integrins on murine osteoclast precursors
58. Inhibition of osteoblast differentiation by tumor necrosis factor-α
59. Tumor necrosis factor-α and interleukin-1β increase the Fas-mediated apoptosis of human osteoblasts
60. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines
61. Etanercept in children with polyarticular juvenile rheumatoid arthritis
62. Infliximab for the treatment of fistulas in patients with Crohn's disease
63. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
64. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection
65. High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: Synergistic action of TNF and IFN-γ in the differentiation of protective granulomas
66. Fatal granuloma necrosis despite intact anti-bacterial functions in TNFRp55-deficient mice chronically infected with M. avium
67. Importance of endogenous tumor necrosis factor-α and gamma interferon in host resistance against Pneumocystis carinii infection
68. Blockade of endogenous TNF-α exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms
69. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to listeria monocytogenes and Leishmania major infections
70. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes
71. Roles for tumor necrosis factor-α and nitric oxide in resistance of rat alveolar macrophages to Legionella pneumophila
72. Antibody-mediated depletion of tumor necrosis factor-α impairs pulmonary host defenses to Legionella pneumophila
73. Tumor necrosis factor induces resistance to Legionella pneumophila infection
74. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating cells
75. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent
76. Interleukin-6 antibodies in rheumatoid arthritis
77. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
78. Etanercept: Therapeutic use in patients with rheumatoid arthritis
79. Treatment of psoriatic arthritis with anti-tumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
80. Efficacy and safety of infliximab monotherapy for plaue-type psoriasis: A randomized trial
81. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
82. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multi-center trial
83. Infliximab for refractory sarcoidosis
84. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis actor-α therapy
85. Immunomodulatory effects of anti-tumor necrosis factor-α therapy on synovium in spondyloarthropathy: Histologic findings in eight patients from an open-label study
86. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor-α monoclonal antibody infliximab
87. Quality of life in patients with severe ankylosing spondylitis in a placebo-controlled multicenter trial
88. A randomized, double-blind placebo-controlled trial of etanercept in the treatment of ankylosing spondylitis
89. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease
90. Etanercept therapy in children with treatment-resistant uveitis
91. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety
92. Infliximab in patients with primary Sjogren's syndrome: A pilot study
93. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
94. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF
95. Development of chronic inflammatory arthrotpathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
96. Altered susceptibility to collagen induced arthritis in transgenic mice with aberrant expression of IL- 1ra
97. IL-1α-1β blockade prevents cartilage and bone destruction in murine type II collagen induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation
98. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts
99. In vivo expression of stromelysin in synovium and cartilage of rabbits injected intra-articularly with interleukin-1β
100. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes
101. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts
102. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
103. Treatment of rheumatoid arthritis with recombinant human interleukin- 1 receptor antagonist
104. The ARMADA trial: A double-blind placebo-controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate
105. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis